Cabazitaxel

Evidence Level: L5 Predicted Indications: 50

Quick Overview

Item Value
Drug Name Cabazitaxel
DrugBank ID DB06772
Brand Names (EU) Jevtana
Evidence Level L5
Predicted Indications 50
Top Prediction Score 99.92%

Approved Indication (EMA)

Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Predicted New Indications

TxGNN model predictions for potential drug repurposing:

Rank Indication Score Source
1 female breast carcinoma 99.92% DL
2 sickle cell-hemoglobin d disease syndrome 99.89% DL
3 hereditary persistence of fetal hemoglobin-sickle cell disease syndrome 99.89% DL
4 sickle cell-beta-thalassemia disease syndrome 99.89% DL
5 sickle cell-hemoglobin c disease syndrome 99.89% DL
6 sickle cell-hemoglobin E disease syndrome 99.89% DL
7 HIV infectious disease 99.82% DL
8 hyperthyroidism 99.77% DL
9 neuroblastoma 99.75% DL
10 rheumatoid arthritis 99.72% DL
11 collagenopathy 99.72% DL
12 lymphocytic hypereosinophilic syndrome 99.70% DL
13 neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter 99.69% DL
14 myeloid leukemia 99.69% DL
15 simian immunodeficiency virus infection 99.69% DL
16 feline acquired immunodeficiency syndrome 99.69% DL
17 resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta 99.67% DL
18 ganglioneuroblastoma (disease) 99.65% DL
19 retroperitoneal neoplasm 99.62% DL
20 vertebral anomalies and variable endocrine and T-cell dysfunction 99.59% DL

Showing top 20 of 50 predictions.

About TxGNN Predictions

Prediction Sources

Source Description
KG Knowledge Graph - Network topology-based associations
DL Deep Learning - Neural network score prediction

Evidence Levels

Level Definition
L1 Multiple Phase 3 RCTs / Systematic Reviews
L2 Single RCT or multiple Phase 2 trials
L3 Observational studies / Large case series
L4 Preclinical / Mechanistic / Case reports
L5 AI prediction only (current)

Clinical Validation Needed

Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.

Next Steps for Validation

  1. Literature Review: Search PubMed for existing evidence
  2. Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
  3. Mechanistic Analysis: Evaluate biological plausibility
  4. Preclinical Studies: Conduct in vitro/in vivo validation
  5. Clinical Trials: Design and conduct human studies

Data Access

Citation

If using this data, please cite:

@article{huang2023txgnn,
  title={A foundation model for clinician-centered drug repurposing},
  author={Huang, Kexin and others},
  journal={Nature Medicine},
  year={2023},
  doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.